- (84) 12345-6789
Each year 500 California children with cancer either lack or fail to respond to standard therapies. Clinical trials currently underway at UC Medical Centers are starting to employ genomic analysis to identify new therapies for these incurable tumors. So far these efforts yield new treatment possibilities for less than 10% of patients, in part because each tumor is analyzed on its own.
The California Kids Cancer Comparison (CKCC) project provides the power of large-scale bioinformatics to improve this outcome. It analyzes each patient’s tumor in the context of thousands of pediatric and adult tumors that have undergone similar characterization. To help rapidly bring state-of-the-art analyses to our clinical collaborators, our team includes UC researchers and physicians in partnership with biotech and computer companies. Through the CKCC, we aim to at least double the number of kids that can benefit from a targeted cancer treatment. The concept can be scaled and applied to other genetic diseases and to all the 147,000 Californians diagnosed with cancer each year.
As part of the CKCC project, we are developing MedBook, a social network designed for medical research and medical decision support. MedBook tools upload, manage and visualize both clinical and genomic data, handling this information in a manner protecting patient privacy. The tools process the genomic data using DNA genomic alignment, RNA sequence expression mapping, and pathway analysis, both at the cohort and the individual patient level. Clinicians and researchers will use MedBook to discuss and collaborate to find the best treatment for each patient, while patients and their advocates will be able to access this information and communicate with providers through this network.
UC Santa Cruz
UC San Francisco
Children’s Hospital of Philadelphia
University of Southern California
UC San Francisco
Translational Genomics Research Institute (TGen)
CARIS Life Sciences
Unravel Pediatric Cancer
Kids v Cancer
Alex's Lemonade Stand Foundation
Team G Foundation
In order to achieve its goals, the CKCC project requires additional funds beyond those provided by CIAPM. The state’s contribution to the project is significantly leveraged by the fact that CKCC will utilize genomic information generated by its clinical trial partners (Stanford University, UC Irvine, UC San Francisco), which represents a total of over $16.5 million in funding.
In addition, portions of several currently funded projects and personnel at UC Santa Cruz and patient advocacy groups contribute over $1.2M to CKCC.